Intention-to-treat analysis
Intention-to-treat analysis (ITT analysis) is a statistical approach used in randomized controlled trials. The ITT analysis includes every subject who is randomized according to randomized treatment assignment. It ignores noncompliance, protocol deviations, withdrawal, and anything that happens after randomization. ITT analysis is intended to avoid various misleading artifacts that can arise in intervention research such as non-random attrition of participants from the study or crossover.
History
The concept of ITT analysis was first introduced in the field of clinical trials in the 1970s. The principle behind this approach is to maintain the benefits of randomization, which is crucial in determining the efficacy of a treatment.
Principle
The principle of ITT analysis is that it includes all participants in the trial regardless of whether they completed or fully adhered to the treatment. This approach is based on the principle of randomization which assumes that every participant has an equal chance of being assigned to the treatment or control group.
Advantages
ITT analysis has several advantages. It preserves the random assignment of treatments, thus maintaining baseline comparability of treatment groups, and it reflects the pragmatic clinical question of the effect of treatment assignment, not of treatment completion.
Disadvantages
Despite its advantages, ITT analysis also has some limitations. It may underestimate the potential benefits of a treatment, as it includes participants who may not have fully adhered to the treatment. It also assumes that the reason for dropout is unrelated to the treatment, which may not always be the case.
Alternatives
Alternatives to ITT analysis include per-protocol analysis and as-treated analysis. Per-protocol analysis includes only those participants who completed the treatment originally allocated. As-treated analysis includes participants according to the treatment they actually received, rather than the one they were assigned to.
See also

This article is a statistics-related stub. You can help WikiMD by expanding it!
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa

Tired of being overweight?
Special offer:
Budget GLP-1 weight loss medications
- Semaglutide starting from $29.99/week and up with insurance for visit of $59.99 and up per week self pay.
- Tirzepatide starting from $45.00/week and up (dose dependent) or $69.99/week and up self pay
✔ Same-week appointments, evenings & weekends
Learn more:
- GLP-1 weight loss clinic NYC
- W8MD's NYC medical weight loss
- W8MD Philadelphia GLP-1 shots
- Philadelphia GLP-1 injections
- Affordable GLP-1 shots NYC
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
